Many new products were approved and launched during Dr Morstyn’s tenure at Amgen Inc., where he had overall responsibility globally for drug development in all therapeutic areas and was a member of the Operating Committee. Prior to joining Amgen, Dr Morstyn was principal investigator on the earliest clinical studies of the haemopoietic colony stimulating factors (CSFs). The CSFs were subsequently approved and launched as a major medical breakthrough used to reduce side effects of chemotherapy and enable transplantation in more than 20 million patients worldwide and have become multi-billion dollar drugs.

Since returning to Australia, Dr Morstyn has served as a Non-Executive Director for several for-profit and not for profit biotechnology companies, including GBS, Chemgenex and Symbio. He was also deputy Chairman of the inaugural board of the Victorian Comprehensive Cancer Centre and the CRC for Cancer therapeutics. He is currently director of Actinogen an ASX listed company.

Dr Morstyn is a medical graduate of Monash University (Australia), with a PhD from the Walter and Eliza Hall Institute of Medical Research (Australia) and a FRACP in Medical Oncology following a Fellowship at the National Cancer Institute in the USA. He is a Member of the Australian Institute of Company Directors and a Fellow of the Australian Academy of Technological Sciences and Engineering.